2seventy bio Inc (TSVT) Actualités

Form 8-K - Current report

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results

$242 million in U.S. Abecma sales in 2024 Approximately $184 million of cash, cash equivalents and marketable securities as of December 31, 2024...

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in...

2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and...